Beactica Therapeutics Advances Glioblastoma Drug BEA-17 to Regulatory Phase

Glioblastoma remains one of the most aggressive primary brain tumors, with standard survival rates hovering around 15 months. Existing immunotherapies have largely failed to penetrate the disease's immunosuppressive, immune-cold microenvironment. BEA-17 aims to bypass these barriers by degrading key epigenetic regulators, which triggers viral mimicry and shifts macrophages into a pro-inflammatory state. Preclinical data indicates the compound significantly improves survival when paired with standard care, providing a potential edge over traditional catalytic inhibitors.

The current development phase involves GLP-compliant toxicology, safety pharmacology, and the production of clinical-grade drug batches. This work is supported by a 2.5 million euro EIC Transition grant under the Horizon Europe project known as GLIOBREAK. Per Källblad, CEO of Beactica, noted that the transition to these rigorous safety and manufacturing protocols is a defining step in readying the drug for first-in-human testing. The company intends to complete these requirements and submit its regulatory applications by 2027. Having already secured Orphan Drug Designation from the FDA, the program represents a critical attempt to break the two-decade stagnation in glioblastoma treatment standards.